Interpretation of commonly used immunohistochemical markers in pathological reports of bladder cancer

doi:10.3877/cma.j.issn.1674-3253.2025.03.003

Abstract

Abstract:

Immunohistochemistry is an important adjunct to the diagnosis， classification， and prediction of the efficacy of targeted therapy and immunotherapy in bladder cancer.This paper presents the commonly used immunohistochemical markers in pathological reports of bladder cancer.In the future， with the application of immunohistochemistry-based molecular subtypes of urothelial carcinoma and artificial intelligence technology，immunohistochemistry will further promote the development of precision diagnosis and treatment of bladder cancer.

Key words: Bladder cancer, Pathological report, Immunohistochemical markers, Precision diagnosis and treatment, antibody-drug conjugates (ADCs)

Hong Zeng. Interpretation of commonly used immunohistochemical markers in pathological reports of bladder cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 296-302.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.03.003

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I03/296

Figures/Tables 5

References 32

［1］	Sung H， Ferlay J， Siegel RL， et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin， 2021， 71（3）： 209-249.DOI： 10.3322/caac.21660.
［2］	Netto G， Amin M， Berney D， et al.The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B： prostate and urinary tract tumors.［J］.Eur Urol，2022， DOI： org/10.1016/j.eururo.2022.07.002
［3］	Wagner T， Toft BG， Lauritsen J， et al.Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma： a nationwide，population-based cohort study［J］.Eur J Cancer， 2024， 202： 114025.DOI： 10.1016/j.ejca.2024.114025.
［4］	Liu G， Kong X， Dai Q， et al.Clinical features and prognoses of patients with breast cancer who underwent surgery［J］.JAMA Netw Open， 2023， 6（8）： e2331078.DOI： 10.1001/jamanetworkopen.2023.31078.
［5］	US Food and Drug Administration （FDA）.FDA grants accelerated approval to sacituzumabgovitecan for advanced urothelial cancer［EB/OL］.https：//www.fda.gov/drugs/resources-informationapproved-drugs/fda-grants-accelerated-approval-sacituzumabgovitecan-advanced-urothelial-cancer.
［6］	Maguire WF， Lee D， Weinstock C， et al.FDA approval summary：enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma［J］.Clin Cancer Res， 2024， 30（10）： 2011-2016.DOI： 10.1158/1078-0432.ccr-23-3738.
［7］	何旺，黄海.2022 ASCO-GU 尿路上皮癌精粹解析［J］.中华泌尿外科杂志， 2022， 43（4）： 245-248.DOI： 10.3760/cma.j.cn112330-20220408-00180.He W， Huang H.Research progress in the diagnosis and treatment of urothelial carcinoma at the 2022 ASCO-GU［J］.Chin J Urol， 2022，43（4）： 245-248.DOI： 10.3760/cma.j.cn112330-20220408-00180.
［8］	Powles T， Huddart RA， Elliott T， et al.Phase III， double-blind，randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer［J］.J Clin Oncol， 2017， 35（1）： 48-55.DOI： 10.1200/JCO.2015.66.3468.
［9］	Wülfing C， Machiels JH， Richel DJ， et al.A single-arm， multicenter，open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma［J］.Cancer， 2009， 115（13）： 2881-2890.DOI： 10.1002/cncr.24337.
［10］	Sheng X， Yan X， Wang L， et al.Open-label， multicenter， phase II study of RC48-ADC， a HER2-targeting antibody-drug conjugate， in patients with locally advanced or metastatic urothelial carcinoma［J］.Clin Cancer Res， 2021， 27（1）： 43-51.DOI： 10.1158/1078-0432.CCR-20-2488.
［11］	范博南，陈凌武.抗体偶联药物治疗转移性尿路上皮癌的临床研究进展［J］.中华泌尿外科杂志， 2023， 44（3）： 230-233.DOI：10.3760/cma.j.cn112330-20220513-00282.Fan BN， Chen LW.Advances in antibody-drug conjugates in the treatment of urothelial carcinoma［J］.Chin J Urol， 2023， 44（3）： 230-233.DOI： 10.3760/cma.j.cn112330-20220513-00282.
［12］	中国抗癌协会肿瘤病理专业委员会，中国临床肿瘤学会尿路上皮癌专家委员会.中国尿路上皮癌HER-2 检测临床病理专家共识［J］.中华肿瘤杂志， 2021， 43（10）： 1001-1006.DOI： 10.3760/cma.j.cn112152-20210809-00597.Tumor Pathology Committee of Chinese Anti-Cancer Association，Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology.Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China［J］.Chin J Oncol， 2021，43（10）： 1001-1006.DOI： 10.3760/cma.j.cn112152-20210809-00597.
［13］	国家病理质控中心，中华医学会病理学分会，中国临床肿瘤学会肿瘤病理专家委员会.实体肿瘤PD-L1 免疫组织化学检测专家共识（2021 版）［J］.中华病理学杂志， 2021， 50（7）： 710-718.DOI：10.3760/cma.j.cn112151-20210228-00172.Pathology Quality Control Center， Chinese Society of Pathology，Pathology Committee of Chinese Society of Clinical Oncology.Consensus on the immunohistochemical tests of PD-L1 in solid tumors （2021 version）［J］.Chin J Pathol， 2021， 50（7）： 710-718.DOI：10.3760/cma.j.cn112151-20210228-00172.
［14］	中华医学会病理学分会泌尿与男性生殖系统疾病病理专家组.膀胱浸润性尿路上皮癌PD-L1（SP263）免疫组织化学检测病理专家共识［J］.中华病理学杂志， 2020， 49（11）： 1102-1107.DOI： 10.3760/cma.j.cn112151-20200316-00206.Expert Group of the Urinary System and Male Genital Organs，Chinese Society of Pathology.Consensus on immunohistochemical detection of PD-L1 （SP263） in bladder invasive urothelial carcinoma［J］.Chin J Pathol， 2020， 49（11）： 1102-1107.DOI： 10.3760/cma.j.cn112151-20200316-00206.
［15］	Höglund M， Bernardo C， Sjödahl G， et al.The Lund taxonomy for bladder cancer classification - from gene expression clustering to cancer cell molecular phenotypes， and back again［J］.J Pathol， 2023，259（4）： 369-375.DOI： 10.1002/path.6062.
［16］	孔家瑾，张璐.膀胱癌分子机制及分子分型的研究进展［J］.临床泌尿外科杂志， 2021， 36（3）： 236-241.DOI： 10.13201/j.issn.1001-1420.2021.03.016.Kong JJ， Zhang L.Advances in molecular mechanism and molecular subtype of bladder cancer［J］.J Clin Urol， 2021， 36（3）： 236-241.DOI：10.13201/j.issn.1001-1420.2021.03.016.
［17］	黄文斌，程亮.膀胱癌分子病理学研究进展［J］.中华病理学杂志，2023， 52（10）： 1074-1078.DOI： 10.3760/cma.j.cn112151-20230227-00155.Huang WB， Cheng L.Research progress in molecular pathology of bladder cancer［J］.Chin J Pathol， 2023， 52（10）： 1074-1078.DOI：10.3760/cma.j.cn112151-20230227-00155.
［18］	Lindskrog SV， Prip F， Lamy P， et al.An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscleinvasive bladder cancer［J］.Nat Commun， 2021， 12（1）： 2301.DOI：10.1038/s41467-021-22465-w.
［19］	Hurst CD， Cheng G， Platt FM， et al.Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological，clinical， and therapeutic insight［J］.Cell Rep Med， 2021， 2（12）：100472.DOI： 10.1016/j.xcrm.2021.100472.
［20］	Jackson CL， Chen L， Hardy CS， et al.Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer［J］.J Pathol Clin Res， 2022， 8（2）：143-154.DOI： 10.1002/cjp2.245.
［21］	Marzouka NAD， Eriksson P， Bernardo C， et al.The Lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma［J］.J Mol Diagn， 2022， 24（9）： 992-1008.DOI： 10.1016/j.jmoldx.2022.05.006.
［22］	Warrick J.Molecular subtypes of bladder cancer： component signatures and potential value in clinical decision-making［J］.Adv Anat Pathol， 2024， 31（3）： 178-187.DOI： 10.1097/PAP.00000 00000000430.
［23］	孙杨，马强，郑克文，等.肌层浸润性膀胱癌分子分型研究进展［J］.浙江医学， 2024， 46（2）： 216-220.DOI： 10.12056/j.issn.1006-2785.2024.46.2.2023-1940.Sun Y， Ma Q， Zheng KW， et al.Progress in molecular typing of myometrial invasive bladder cancer ［J］.Zhejiang Med J， 2024， 46（2）：216-220.DOI： 10.12056/j.issn.1006-2785.2024.46.2.2023-1940.
［24］	Warrick JI， Al-Ahmadie H， Berman DM， et al.International society of urological pathology consensus conference on current issues in bladder cancer.working group 4［J］.Am J Surg Pathol， 2024， 48（1）：e32-e42.DOI： 10.1097/pas.0000000000002053.
［25］	Bejrananda T， Kanjanapradit K， Saetang J， et al.Impact of immunohistochemistry-based subtyping of GATA3， CK20， CK5/6，and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer［J］.Sci Rep， 2021， 11（1）： 21186.DOI： 10.1038/s41598-021-00628-5.
［26］	祝颖，蒋智铭，周隽，等.基于免疫组化的膀胱浸润性尿路上皮癌的分子分型［J］.临床与实验病理学杂志， 2022， 38（3）： 368-371.DOI： 10.13315/j.cnki.cjcep.2022.03.028.Zhu Y， Jiang ZM， Zhou J， et al.Molecular typing of bladder invasive urothelial carcinoma based on immunohistochemistry ［J］.J Clin Exp Pathol， 2022， 38（3）： 368-371.DOI： 10.13315/j.cnki.cjcep.2022.03.028.
［27］	Pan J， Hong G， Zeng H， et al.An artificial intelligence model for the pathological diagnosis of invasion depth and histologic grade in bladder cancer［J］.J Transl Med， 2023， 21（1）： 42.DOI： 10.1186/s12967-023-03888-z.
［28］	Wu S， Hong G， Xu A， et al.Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer： a retrospective， multicentre， diagnostic study［J］.Lancet Oncol， 2023， 24（4）： 360-370.DOI： 10.1016/s1470-2045（23）00061-x.
［29］	Wu S， Yue M， Zhang J， et al.The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer［J］.Mod Pathol， 2023， 36（3）： 100054.DOI：10.1016/j.modpat.2022.100054.
［30］	Cai L， Yan K， Bu H， et al.Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope： a multi-institutional ring study［J］.Histopathology， 2021， 79（4）： 544-555.DOI： 10.1111/his.14383.
［31］	Wang X， Wang L， Bu H， et al.How can artificial intelligence models assist PD-L1 expression scoring in breast cancer： results of multiinstitutional ring studies［J］.NPJ Breast Cancer， 2021， 7（1）： 61.DOI：10.1038/s41523-021-00268-y.
［32］	Hondelink LM， Hüyük M， Postmus PE， et al.Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer［J］.Histopathology， 2022，80（4）： 635-647.DOI： 10.1111/his.14571.

免疫组化染色模式	评分标准
无着色或＜10%浸润性癌细胞膜不完全且微弱染色	0
≥10%浸润性癌细胞膜不完全且微弱染色	1+
≥10%浸润性癌细胞膜弱-中等强度的完整胞膜染色或＜10%浸润性癌细胞完整细胞膜强染色	2+
≥10%浸润性癌细胞完整细胞膜强染色	3+

免疫组化染色模式	评分标准
无着色或＜10%浸润性癌细胞膜不完全且微弱染色	0
≥10%浸润性癌细胞膜不完全且微弱染色	1+
≥10%浸润性癌细胞膜弱-中等强度的完整胞膜染色或＜10%浸润性癌细胞完整细胞膜强染色	2+
≥10%浸润性癌细胞完整细胞膜强染色	3+

检测试剂	对应药物	适用人群	肿瘤细胞判读标准	免疫细胞判读标准	临床试验阳性阈值
Dako 22C3	帕博利珠单抗	顺铂类化疗不耐受的局部晚期或转移性尿路上皮癌^a	CPS	CPS	CPS≥10
Dako28-8	纳武利尤单抗	尿路上皮癌	肿瘤细胞	无需评估	肿瘤细胞≥1%
Ventana SP142	阿替利珠单抗	晚期尿路上皮癌^a	无需评估	IC	IC≥5%
Ventana SP263	替雷利珠单抗	局部晚期或转移性尿路上皮癌^b	TC	IC+	TC≥25%；或ICP＞1%且IC+≥25%；或ICP=1%且IC+=100%
Ventana SP263	度伐利尤单抗	尿路上皮癌	TC	IC+	TC≥25%；或ICP＞1%且IC+≥25%；或ICP=1%且IC+=100%

检测试剂	对应药物	适用人群	肿瘤细胞判读标准	免疫细胞判读标准	临床试验阳性阈值
Dako 22C3	帕博利珠单抗	顺铂类化疗不耐受的局部晚期或转移性尿路上皮癌^a	CPS	CPS	CPS≥10
Dako28-8	纳武利尤单抗	尿路上皮癌	肿瘤细胞	无需评估	肿瘤细胞≥1%
Ventana SP142	阿替利珠单抗	晚期尿路上皮癌^a	无需评估	IC	IC≥5%
Ventana SP263	替雷利珠单抗	局部晚期或转移性尿路上皮癌^b	TC	IC+	TC≥25%；或ICP＞1%且IC+≥25%；或ICP=1%且IC+=100%
Ventana SP263	度伐利尤单抗	尿路上皮癌	TC	IC+	TC≥25%；或ICP＞1%且IC+≥25%；或ICP=1%且IC+=100%

[1]	Haixia He, Shoumin Bai. The utilization of radiotherapy in bladder-sparing treatment for muscle-invasive bladder cancer and the refinement of strategies to minimize toxicity [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 288-295.
[2]	Shiwang Huang, Yunkai Qie, Hailong Hu. Application of artificial intelligence in non-invasive urine-based diagnostic methods for bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 283-287.
[3]	Qing Xue, Saiye Shi, Yawen Xu, Xia Sheng, Qinqin Zhang. Application of tracking methodology combined with failure mode and effect analysis in patients with bladder perfusion chemotherapy [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 553-559.
[4]	Yi Lin, Wenlong Zhong, Kaiwen Li, Wang He, Tianxin Lin. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 15）: comprehensive treatment of metastatic bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 648-652.
[5]	Mingyang Pang, Yong Wei, Luming Shen, Qingyi Zhu. Domestic single port robot-assisted laparoscopic partial cystectomy via pneumatic bladder approach for bladder cancer: a case report [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 638-643.
[6]	Zhongwen Liu, Chang Liu, Yang Gao, Dong Liu, Shiqing Lin, Jianhua Yang, Fuyi Zhao. Correlation of urinary microRNA-326 with the prognosis of bladder cancer patients treated with radical cystectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 386-391.
[7]	Chengbo Qian, Huming Yin, Feng Qiu, Jianquan Hou, Yuhua Huang, Xuedong Wei. Evaluation of laparoscopic radical cystectomy with W-shaped ileal neobladder in the elderly [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 346-352.
[8]	Minimally Invasive Surgery Professional Committee of the Chinese Research Hospital Association The, Intelligent Medicine Professional Committee of the Chinese Research Hospital Association The. Expert consensus on robotic radical resection for gallbladder cancer [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2025, 18(02): 78-82.
[9]	Botao Chen, Kuan Hu, Xianhai Mao. Tumor microenvironment and systematic treatment of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 203-208.
[10]	Qingguang Liu, Zhimin Geng, Dong Zhang, Qi Li. Current status and thinking of minimally invasive radical cholecystectomy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 158-166.
[11]	Kecan Lin, Liuping Luo. Key problems in the application of hepatopancreaticoduodenectomy for gallbladder cancer and cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 774-778.
[12]	Dawen Zheng, Jiandong Wang. Research progress in adjuvant diagnosis of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 769-773.
[13]	Weijie Chen, Xiaodong He. Progress in immunotargeted therapy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 763-768.
[14]	Di Zhou, Zhiwei Quan. Standardization on diagnosis and treatment process of benign gallbladder diseases to reduce misdiagnosis and inappropriate treatment [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 749-753.
[15]	Hongsheng Ji, Wanqing Wei, Jianguo Qiu, Liucheng Wang, Fujin Jiang, Xianyun Zhang, Sugui Wang. Expression of KPNB1 in bladder cancer and its role in proliferation and migration of bladder cancer cells [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(11): 1044-1053.

Please choose a citation manager

Content to export